{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations during treatment.\n\nComplete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and \\<5% plasma cells in bone marrow.\n\nVery Good Partial Response(VGPR): \\>=90% reduction in serum M-component; Urine M-Component \\<=100 mg per 24 hours.\n\nPartial Response(PR): \\>=50% reduction in serum M-component and/or Urine M-Component \\>=90% reduction or \\<200 mg per 24 hours; or \\>=50% decrease in difference between involved and uninvolved FLC levels.","groups":[{"description":"Lenalidomide (Len) 15mg daily (days 1-21); Cyclophosphamide (Cyc) 300 mg/m\\^2 (days 1, 8, 15); Dexamethasone (Dex) 40 mg weekly","id":"OG000","title":"Len/Cyc/Dex"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration on study (up to 3 years)","title":"Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR)","type":"PRIMARY","unitOfMeasure":"participants"}